- To submit a COVID-19-related abstract, a non-refundable processing fee of EUR 100 will be charged at the time of online submission. Authors of rejected, incomplete or wrongly submitted abstracts will not be refunded.
- Abstract submission must be in one of the diﬀerent tracks:
There will be no sub-categories, but all COVID/RMD-related science is welcome: mechanistic, clinical, therapeutic, public health, etc.
Splitting of data originating from the same study across several abstracts and/or topics is not permitted and will lead to rejection of the abstracts.
It is mandatory to use the abstract word template provided by the system. Please read all instructions carefully before preparing your abstract.
- For standardisation, the character limit is 3600 including:
- Author first names, middle initials and last names
- Author affiliations
- Acknowledgements including working group
- Working group + “on behalf of” if entered
- Headings and content of the abstract word template.
- The abstract word template is structured into the following sections:
- Characters from table content including title and footnotes.
- Extra, not part of 3600 characters: Abstract title (min 15, maximum 300 characters)
- Characters not counted, but part of final abstract
- Abstract number
- Conflict of Interest
- invisible characters such as spaces
- Tables (characters included count): A maximum of two tables can be included in the abstract word template with the following criteria: Combined maximum number of columns: 12 / rows: 20
Graphs / Images: A maximum of two graphs/images can be included. Tables turned into pictures/images are not accepted.
COVID-19-related abstracts can be re-edited and modiﬁed until the submission deadline (20 May 2020, 23:59 CET). Please ensure that your abstract does not contain spelling, grammatical or scientiﬁc errors, as it will be reproduced exactly as submitted. No proofreading will be done.
COVID-19-related abstracts accepted for the congress are subject to the EULAR embargo rules. With the submission of a abstract the authors agree to the embargo rules.
Conﬂict of interest: It is the intent of EULAR to provide high quality sessions focused on educational content that is free from commercial inﬂuence or bias. Thus the submitting author of an abstract is requested to declare any potential conﬂicts of interest for all authors during the abstracts submission.
For clinical abstract submissions, the presenting author can be any of the listed authors without affiliations to industry.
For basic and translational abstract submissions, the presenting author can be any of the listed authors.
The inclusion of trade names/brand names is not allowed in the abstract. The mentioning of agents/molecules must follow the scientiﬁc standard for publications.
The corresponding author has the right to grant, and does grant, on behalf of all authors an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd and EULAR to publish the abstract (if accepted) in any media and to exploit all subsidiary rights.
Only COVID-19-related abstracts that contain original data can be submitted.
COVID-19-related abstracts will be reviewed blinded. The reviewers will judge the abstracts according to the scientiﬁc or clinical value, relevance to EULAR, suitability of methods to aims, conclusions conﬁrmed by objective results, objectivity of statements, description of methods used, ethics, originality of work, standard of English and overall impression.
COVID-19-related abstract acceptance will be as oral or poster presentation.
Should the COVID-19-related abstract be selected for oral presentation, the authors, represented by the presenting author will be required to sign an agreement to grant EULAR the right to record the presentation (audio and slide) and subsequently use it for educational purposes (with or without a fee). The full text of the agreement, the publication licence, can be found on the right side of the column.
Accepted COVID-19-related abstracts will be published in a supplement to the Annals of Rheumatic Diseases (ARD) or as electronic pages at the end of a regular issue. Information on accepted abstracts (title and authors) will be available online prior to the congress. Published abstracts will be available in the EULAR Abstract Archive during and after the congress.
The submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) in the session and the time assigned by the EULAR Scientiﬁc Programme Committee. We therefore recommend submitters of COVID-19-related abstracts to register for the congress at the time of abstract submission.
Abstracts not adhering to these guidelines will be rejected. If you do not agree with any of these rules, you should not submit a COVID-19-related abstract. The ﬁnal decision about acceptance of a abstract will be taken by the EULAR Scientiﬁc Programme Committee. EULAR does not communicate, nor enter into correspondence on the reasons for acceptance/rejection of an abstract.
Withdrawal of your abstract is not possible after final submission (20 May 2020 23:59 CET).